Tweets
Year in Review: Dr. P Seo
Dr. Seo gave a moment of silence to Baricitinib use in SLE given studies showing it is not efficacious for SLE
#ACR23 @RheumNow https://t.co/8GKUlfJdbe
Meral K. El Ramahi, MD @MeralElRamahiMD ( View Tweet )
2 years 3 months ago
Year in Review: Dr. P Seo
Novel PsA therapy on the horizon:
⭐️Bimekizumab
➡️ Anti-IL17A, ANti-IL17F ab
🚩BE COMPLETE
➡️ TNFi failures
➡️Phase III, 400 pts, bimekizumab, PBO
➡️ Wk 16: improvements in joint and skin
#ACR23 @RheumNow
Meral K. El Ramahi, MD @MeralElRamahiMD ( View Tweet )
2 years 3 months ago
Year in Review: Dr. P Seo
Novel PsA therapy on the horizon:
⭐️Bimekizumab
➡️ Anti-IL17A, ANti-IL17F ab
🚩BE OPTIMAL
➡️ tx-naive
➡️Phase III, 852 pts, bimekizumab, PBO, ADA
➡️ Wk 16: same as ADA for joints, BETTER FOR SKIN
#ACR23 @RheumNow
Meral K. El Ramahi, MD @MeralElRamahiMD ( View Tweet )
2 years 3 months ago
Year in Review: Dr. P Seo
Novel PsA therapy on the horizon:
⭐️Brepocitinib
➡️ Tyk-2 inhibitor: IL12/23 & type I IFN
➡️ Phase Ib, 218 pts, 8% TNFi failure
➡️ 71% on concurrent MTX
➡️ Wk 16: ACR 50/70 & PASI75/90 improved, maintained through week 52
#ACR23 @RheumNow
Meral K. El Ramahi, MD @MeralElRamahiMD ( View Tweet )
2 years 3 months ago
These US Medicare data show us what we've all suspected:
PMR patients stuck on steroid get the fractures, heart attacks, & infections that land them in hospital.
And it costs $$$
Hopefully PMR steroid-sparing Rx can change this!
@RADoctor @SattuiSEMD #ACR23 ABST0718 @RheumNow https://t.co/XAWmf2qZAU
David Liew @drdavidliew ( View Tweet )
2 years 3 months ago
Year in Review: Dr. P Seo
Novel RA therapy on the horizon:
⭐️ABBV-3373
➡️ Adalimumab (ADA) + GC receptor modulator vs ADA
➡️ Phase II, 48 pts, previously failed MTX
➡️ Wk 12: better DAS28-CRP, ACR20/70
🚩71% of responders stayed in remission after switch to PBO
#ACR23 @RheumNow
Meral K. El Ramahi, MD @MeralElRamahiMD ( View Tweet )
2 years 3 months ago
Difficult to treat RA is not an homogeneous group!
Trajectory analysis 60months shows 4 different clusters
Cluster 2 = 1/3 of patients, do better but never reach LDA.
The ones Fibromyalgia, OA and other conditions blurring assessment?
#Abstract0382 #ACR23 @RheumNow https://t.co/dxxS7vCcMt
Aurelie Najm ( View Tweet )
2 years 3 months ago
Dr. Arbeeva explains how a "modern diet" can lead to MetS, intestinal dysbiosis & obesity - risk factors assoc w/ development of #osteoarthritis
Modern diet:
⬆️calorie processed food
⬇️proportion of fruits & veggies
⬆️ratio of omega-6 FA:omega-3FA
#ACR23 @rheumnow @rheumarhyme https://t.co/biVSE103S0
sheila ( View Tweet )
2 years 3 months ago
Year in Review: Dr. P Seo
⭐️Low dose colchicine assoc w/ ⬇️ incidence of hip/knee replacement
➡️ 5522 pts w/ stable CAD: colchicine 0.5 mg vs PBO for median of 28.6 months
➡️ Hip/knee: 2.5% vs 3.5%
➡️HR 0.69
Similar finding in 2020 CANTOS trial using Ilaris
#ACR23 @RheumNow https://t.co/PD26zoolDB
Meral K. El Ramahi, MD @MeralElRamahiMD ( View Tweet )
2 years 3 months ago
Calling #rheumtwitter program directors! #ACR23 Plenary 0726 details considerations for developing MSUS curriculum from Canadian experts. Details below. https://t.co/VmbxkYwlcr @rheumnow https://t.co/5nrpDk0Dsc
Dr. Rachel Tate ( View Tweet )
2 years 3 months ago
Thinking beyond immunosuppression for SLE Nephritis management:
SGLT-2i
GLP-1RA
ERAs
@RheumNow #ACR23 https://t.co/RdmKnm08YY
Robert B Chao, MD ( View Tweet )
2 years 3 months ago
Love teaching about the PsA-AxSpa-IBD venn diagram of disease manifestations
Interesting idea, using fecal calprotectin to trigger colonoscopy in pts w/PsA/axSpA
~40% w/pathologic finding, 4.4% dx w/IBD
Jives w/my clinical experience
@RheumNow #ACR23 Abstr0495 #ACRBest https://t.co/rIQpJnup9v
Mike Putman @EBRheum ( View Tweet )
2 years 3 months ago
